

CITATION REPORT

List of articles citing

Postmenopausal use of estrogen and occlusion of coronary arteries

DOI: 10.1016/0002-8703(88)90063-4
American Heart Journal, 1988, 115, 954-63.

Source: <https://exaly.com/paper-pdf/19723958/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
301	Oestrogen replacement therapy and cardiovascular disease in post-menopausal women. A review. 1989 , 11, 259-74		29
300	Smoking, estrogen, and prevention of heart disease in women. 1989 , 64, 1553-7		2
299	Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone. 1990 , 97, 1093-100		31
298	Clinical pharmacology and therapeutics. 1990 , 66, 166-85		4
297	Estrogen Replacement and Coronary Artery Disease. 1990 , 150, 2557		204
296	Body fat distribution and male/female differences in lipids and lipoproteins. 1990 , 81, 1498-506		150
295	Ovarian hormones and the circulation. 1990 , 12, 287-98		148
294	Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. 1990 , 162, 1534-9; discussion 1539-42		108
293	Estrogen and cardiovascular disease. 1990 , 592, 286-94; discussion 334-45		50
292	Risks of estrogens and progestogens. 1990 , 12, 215-46		34
291	Sex hormones and coronary disease: a review of the clinical studies. 1990 , 55, 330-52		236
290	Endothelium-independent relaxation of rabbit coronary artery by 17 beta-oestradiol in vitro. 1991 , 104, 1033-7		285
289	Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. 1991 , 165, 307-15; discussion 315-7		46
288	Oestrogen therapy and cardiovascular disease: do the benefits outweigh the risks?. 1991 , 5, 889-913		1
287	Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. 1991 , 20, 47-63		1361
286	Estrogen and Coronary Heart Disease in Women. 1991 , 265, 1861		681
285	Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. 1991 , 325, 756-62		1800

284	Extraskeletal effects of estrogen and the prevention of atherosclerosis. 1991 , 2, 5-11	30
283	Postmenopausal hormone replacement therapy. 1992 , 305, 1403-8	54
282	Hormone replacement therapy and cardiovascular disease. 1992 , 48, 276-308	63
281	Hormone replacement therapy. Protection against the consequences of menopause. 1992 , 92, 145-8, 151-2, 157-9	9
280	Hormone therapy to prevent disease and prolong life in postmenopausal women. 1992 , 117, 1016-37	1615
279	The effect of oestrogen on the female cardiovascular system. 1992 , 157, 204-8	60
278	Combination of estradiol-valerate and cyproterone acetate a modern regimen for hormone replacement therapy. 1992 , 9-16	1
277	Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. 1992 , 69, 176-8	157
276	Ovarian sex steroids and atherosclerosis. 1993 , 71, 406-12	32
275	Value of a simple measure of estrogen status for improving the diagnosis of coronary artery disease in women. 1993 , 94, 491-496	52
274	Estrogen and estrogen-progestogen replacement: therapy and cardiovascular diseases. 1993 , 95, 405-435	18
273	Blood flow variations in internal carotid and middle cerebral arteries induced by postmenopausal hormone replacement therapy. 1993 , 169, 1226-32	111
272	Oestrogens and atherosclerotic vascular disease--lipid factors. 1993 , 7, 61-93	38
271	Epidemiological overview of oestrogen replacement and cardiovascular disease. 1993 , 7, 95-112	13
270	Cardiovascular protection by oestrogen--a calcium antagonist effect?. 1993 , 341, 1264-5	250
269	From The Lancet. 1993 , 341, 1265	
268	Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. 1993 , 342, 133-6	378
267	Effect of progestogens on estrogen-induced lipoprotein changes. 1993 , 49, 169-74	10

266	Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. 1993 , 88, 2163-71	164
265	Hormone Replacement Therapy and the Risk of Stroke. 1993 , 153, 1201	113
264	Prevention of coronary disease in women. 1993 , 38, 103-6	1
263	Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. 1993 , 137, 1125-35	120
262	A Review of the Association of Estrogens and Progestins With Cardiovascular Disease in Postmenopausal Women. 1993 , 153, 1421	49
261	Hormone Replacement Therapy and Future Risks of Arterial Disease. 1993 , vmr-4, 161-170	
260	Hormone Replacement Therapy in Women with a History of Breast Carcinoma. 1994 , 8, 179-195	6
259	Coronary disease: are there gender differences?. 1994 , 15, 409-17	19
258	Coronary heart disease, the menopause, and hormone replacement therapy. 1994 , 71, 213-4	5
257	Feminist empiricism as a method for inquiry in nursing. 1994 , 16, 480-94	10
256	Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. 1994 , 89, 1501-10	403
255	17 beta-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. 1994 , 89, 2251-9	205
254	Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. 1994 , 90, 1964-8	148
253	Major Issues Regarding Estrogen Replacement Therapy in Postmenopausal Women. 1994 , 3, 273-282	6
252	Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women. 1994 , 29, 357-75	65
251	Unanswered questions in hormonal replacement therapy. 1994 , 29, 447-61	3
250	Issues in design, measurement, and analysis for menopause research. 1994 , 29, 479-93	21
249	Transdermal oestradiol and cardiovascular risk factors. 1994 , 101, 571-81	19

248	Postmenopausal hormone therapy and atherosclerotic disease. <i>American Heart Journal</i> , 1994 , 128, 1337-43	60
247	Heart disease in the assessment and treatment of hypercholesterolemia: coronary artery disease and other atherosclerotic disease, family history, and left ventricular hypertrophy. 1994 , 96, 9S-18S	5
246	Dyslipidemias and the secondary prevention of coronary heart disease. 1994 , 40, 369-464	
245	Postmenopausal hormone replacement therapy and cardiovascular risk reduction. A review. 1994 , 47 Suppl 2, 16-24	40
244	Postmenopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins. 1994 , 47 Suppl 2, 25-34	19
243	Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease. 1994 , 5, 513-54	16
242	Trophic factors in aging. Should older people receive hormonal replacement therapy?. 1994 , 4, 492-509	33
241	Coronary heart disease risk factors in women. 1994 , 15, 1571-84	61
240	Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. 1994 , 121, 936-41	536
239	Southwestern Internal Medicine Conference: postmenopausal estrogen supplementation: a cardiologist's perspective. 1994 , 308, 63-73	3
238	Amenorrhea during the reproductive years--is it safe?. 1994 , 62, 1-16	72
237	The prevention of cardiovascular disease. Emphasis on secondary prevention. 1994 , 78, 69-98	23
236	Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women. 1995 , 35, 1-16	18
235	Estrogen Improves Endothelium-Dependent, Flow-Mediated Vasodilation in Postmenopausal Women. 1995 , 50, 528-530	
234	Acute effect of oestrogen replacement therapy on treadmill performance in postmenopausal women with coronary artery disease. 1995 , 16, 1566-70	17
233	Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women. 1995 , 35, 314-29	37
232	Serum Lipid and Lipoprotein Levels in Postmenopausal Women: Short-Course Effect of Caigua. 1995 , 2, 225-234	5
231	Coronary risk factors and their modification: Lipids, smoking, hypertension, estrogen, and the elderly. 1995 , 20, 539-610	8

230	The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. 1995 , 38, 199-210	326
229	Coronary arteriography in estrogen-treated postmenopausal women. 1995 , 38, 211-22	17
228	Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians' viewpoint. 1995 , 238, 389-99	13
227	Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. 1995 , 142, 1011-9	95
226	Syndrome X in women is associated with oestrogen deficiency. 1995 , 16, 610-4	97
225	Estradiol Specific Binding by Endothelial Cells and its Limited Effect on Von Willebrand Factor Expression. 1995 , 3, 131-139	3
224	Benefit/risk of estrogen therapy in cardiovascular disease: current knowledge and future challenges. 1995 , 35, 11S-17S	12
223	Continuous combined estrogen/progestin hormone replacement therapy. 1995 , 17, 812-26; discussion 811	7
222	Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study. 1995 , 22, 105-14	26
221	Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism. 1995 , 22, 121-30	20
220	The transitional years and beyond. 1995 , 85, 1-5	14
219	Human vascular smooth muscle cells express an estrogen receptor isoform. 1995 , 377, 103-8	35
218	Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood--a beneficial effect on atherogenesis and thrombus formation?. 1995 , 173, 1816-20	40
217	Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. 1995 , 26, 807-14	147
216	Estrogen and cardiovascular function after menopause. 1995 , 26, 1403-10	76
215	Hormonsubstitution in der Postmenopause. 1995 , 256, S193-S197	
214	New approaches to the prevention of atherosclerosis. 1995 , 50, 440-53	18
213	Pharmacokinetics of Estradiol and Estrone following Repeated Administration of Menorest [®] , a New Estrogen Transdermal Delivery System, in Menopausal Women. 1995 , 10, 96-103	8

212	Bioavailability Study of Menorest [®] , a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System. 1995 , 10, 172-8	17
211	Postmenopausal estrogen and heart disease. 1995 , 118, S7-S10	10
210	Estrogens, menopause, and coronary artery disease. 1996 , 14, 105-16	23
209	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. 1996 , 27, 991-1006	43
208	Estrogen replacement therapy. 1996 , 101, 4A56S-59S; discussion 59S-60S	16
207	The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. 1996 , 23, 227-34	48
206	Vascular aspects of oestrogen. 1996 , 23, 217-26	43
205	The clinical aspects of estrogen and the cardiovascular system. 1996 , 87, 36S-43S	46
204	Relaxant effects of 17 beta-estradiol in the rat tail artery are greater in females than males. 1996 , 308, 305-9	22
203	Estrogens protect against hydrogen peroxide and arachidonic acid induced DNA damage. 1996 , 1299, 155-9	28
202	Superior and distinct antioxidant effects of selected estrogen metabolites on lipid peroxidation. 1996 , 45, 411-4	70
201	The impact of female sex hormones on secondary prevention of atherosclerosis in ovariectomized cholesterol-fed rabbits. 1996 , 123, 139-44	31
200	The menopause and the cardiovascular system. 1996 , 10, 483-513	7
199	Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. CHS Collaborative Research Group. Cardiovascular Health Study. 1996 , 6, 314-23	46
198	Hormone replacement therapy in the aged. A state of the art review. 1996 , 8, 193-213	13
197	Hormone Replacement and Cardiovascular Disease in Older Women. 1996 , 5, 351-361	
196	Selection Bias in HRT Epidemiology. 1996 , 2, 29-29	
195	Clinical Trials Report: Oncologic, Endocrine & Metabolic: Clinical trials in progress with hormone replacement therapy. 1996 , 5, 739-749	7

194	Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. 1996 , 93, 10022-7	208
193	Psychosocial factors, sex differences, and atherosclerosis: lessons from animal models. 1996 , 58, 598-611	106
192	Oestrogen as a calcium channel blocker. 1996 , 17 Suppl D, 27-31	25
191	Coronary Heart Disease in Women: Epidemiology, Clinical Syndromes, and Management. 1996 , 3, 51-59	3
190	17 β -Estradiol inhibits proliferation and migration of human vascular smooth muscle cells: similar effects in cells from postmenopausal females and in males. 1996 , 32, 980-985	2
189	Reproductive health of the young and the elderly in the USA. 1996 , 12, 297-303	
188	Estradiol-17beta as an antioxidant: some distinct features when compared with common fat-soluble antioxidants. 1996 , 128, 367-75	95
187	Oestrogen receptors and cardiovascular disease. 1996 , 23, 537-48	16
186	Effects of 17 β -estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro. 1996 , 32, 516-523	3
185	Cardioprotective effects of ovarian hormones. 1996 , 17 Suppl D, 15-9	29
184	Practical aspects of preventing and managing atherosclerotic disease in post-menopausal women. 1996 , 17 Suppl D, 32-7	17
183	Vascular wall, dynamics and estrogen. 1996 , 10, 99-103	
182	Clinical review 91: Female sex hormones and cardiovascular disease in women. 1997 , 82, 3913-8	102
181	Increased collateral blood flow to ischemic myocardium by estrogen replacement therapy may contribute to reduced incidence of fatal and non-fatal acute myocardial infarction in postmenopausal women. 1997 , 5, 139-41	6
180	Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. 1997 , 67, 57-62	73
179	The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. 1997 , 135, 73-81	56
178	Estrogen replacement therapy and cognitive function in postmenopausal women without dementia. 1997 , 103, 26S-35S	53
177	Menopause and post-menopause. 1997 , 11, 311-40	27

176	Long-term sequelae of hormone replacement therapy: benefits and risks. 1997 , 7, 204-211	
175	Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations. 1997 , 71, 193-7	40
174	Coronary Revascularization in Women. 1997 , 9, 497-509	4
173	Regulation of vascular tone and endothelial function and its alterations in cardiovascular disease. 1997 , 11, 531-560	2
172	Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. 1997 , 79, 847-50	93
171	Alteration of ascending thoracic aorta compliance after treatment with menotropin. 1997 , 176, 1255-9; discussion 1260-1	12
170	Sex hormones and vascular reactivity. 1997 , 22, 141-50	16
169	[Estrogens for prevention of coronary heart disease?]. 1997 , 22, 151-7	
168	Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease. 1997 , 19, 230-8	15
167	Effects of 17beta-estradiol on action potentials and ionic currents in male rat ventricular myocytes. 1997 , 356, 788-96	37
166	The anti-mitogenic activity of 17beta-estradiol in coronary smooth muscle cells correlates with protein binding to its responsive element. 1997 , 33, 738-41	
165	Sex steroids and the cardiovascular system. 1997 , 7 Suppl 1, S8-11	4
164	Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. 1998 , 19, 314-35	155
163	Atherosclerotic risks from chemicals: part I. Toxicological observations and mechanisms of atherosclerosis. 1998 , 35, 152-64	9
162	Cardiovascular disease in postmenopausal women. 1998 , 30, 11-8	8
161	Coronary heart disease in women, randomized clinical trials, HERS and RUTH. 1998 , 31, 1-7	35
160	A critical European view of the HERS trial. 1998 , 31, 15-9	3
159	17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. 1998 , 1406, 169-74	123

158	Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimal hyperplasia or arterial remodeling induced by balloon catheter injury in monkeys. 1998 , 31, 1158-64	30
157	Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. 1998 , 31, 1555-60	99
156	Postmenopausal hormone therapy. Is it useful for coronary prevention?. 1998 , 16, 17-25	13
155	Concentration dependence of prooxidant and antioxidant properties of catecholestrogens. 1998 , 360, 105-12	59
154	Choosing the most appropriate treatment for stable angina. Safety considerations. 1998 , 19, 23-44	33
153	Antioxidant protection of LDL by physiologic concentrations of estrogens is specific for 17-beta-estradiol. 1998 , 138, 255-62	53
152	Estrogens and postprandial lipid metabolism. 1998 , 141 Suppl 1, S105-7	8
151	Hormone replacement therapy, heart disease, and other considerations. 1998 , 19, 55-72	411
150	Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. 1998 , 12, 43-59	70
149	Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography. 1998 , 18, 1101-7	56
148	Management of older persons after myocardial infarction. 1998 , 46, 1459-68	10
147	Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. 1998 , 18, 1844-54	55
146	Chronic hormone replacement therapy does not alter resting or maximal skin blood flow. 1998 , 85, 505-10	16
145	Hormone replacement therapy and cardioprotection in the elderly. 1998 , 91, 475-8	1
144	Hemodynamic effect of 17 beta-estradiol in absence of NO in ovariectomized rats: role of angiotensin II. 1998 , 274, R970-8	2
143	Gender differences in coronary artery diameter reflect changes in both endothelial Ca ²⁺ and eNOS activity. 1999 , 276, H961-9	54
142	17Beta-estradiol decreases nitric oxide synthase II synthesis in vascular smooth muscle cells. 1999 , 140, 2004-9	51
141	Raloxifene, a new selective estrogen receptor modulator. 1999 , 39, 767-74	12

140	The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. 1999 , 33, 1315-28	13
139	A New Look at Menopausal Hormone Replacement: Evidence-Based Observations. 1999 , 5, 4-10	1
138	Estrogen stimulates neuronal nitric oxide synthase protein expression in human neutrophils. 1999 , 85, 1020-6	87
137	Effect of age on the exercise response in normal postmenopausal women during estrogen replacement therapy. 1999 , 8, 1273-9	1
136	Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. 1999 , 13, 130-44	46
135	Androgen cotherapy in menopause: evolving benefits and challenges. 1999 , 180, S308-11	21
134	Cardiovascular pharmacology of hormone replacement therapy. 1999 , 15, 219-34	21
133	Screening for cardiovascular disease. Concepts, conflicts, and consensus. 1999 , 83, 1339-73	3
132	Modification of serum lipids and cardiovascular risk by estrogenic active compounds. 1999 , 13 Suppl 6, 21-8	2
131	Antioxidant protection of lipoproteins containing estrogens: in vitro evidence for low- and high-density lipoproteins as estrogen carriers. 1999 , 1439, 331-40	20
130	Reproductive history and cardiovascular disease risk in postmenopausal women: a review of the literature. 1999 , 33, 7-36	85
129	ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). 1999 , 33, 2092-197	482
128	Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodeling. 1999 , 34, 1427-34	27
127	Hormone replacement therapy and ischaemic heart disease among postmenopausal women. 1999 , 6, 105-12	6
126	Hormone replacement therapy and intima-media thickness of the common carotid artery: the Rotterdam study. 1999 , 30, 2562-7	67
125	Estrogen improves abnormal norepinephrine-induced vasoconstriction in postmenopausal women. 1999 , 17, 523-8	51
124	Hormone replacement therapy and cardiovascular disease. 1999 , 10, 581-7	6
123	Hormone replacement therapy and peripheral arterial disease: the Rotterdam study. 2000 , 160, 2498-502	45

122	Controversial issues in climacteric medicine I. Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop. 13-16 October 2000, royal society of medicine, London, UK. 2000 , 3, 233-40	36
121	Acute modulation of Ca ²⁺ influx on rat heart by 17beta-estradiol. 2000 , 12, 47-52	19
120	Hormone replacement therapy should not be used as secondary prevention of coronary heart disease. 2000 , 20, 1021-7	2
119	Hormone replacement therapy should be administered as secondary prevention of coronary artery disease. 2000 , 20, 1028-33	1
118	Complete and selective estrogenic effects on lipids and cardiovascular disease. 2000 , 2, 72-5	2
117	Postmenopausal hormone replacement therapy and the vascular wall: epidemiology and clinical studies. 2000 , 29, 243-51	3
116	17 Beta-Estradiol Stimulated Nitric Oxide Production by Neutrophils. 2000 , 95, 284-290	2
115	Testosterone supplemental therapy after hysterectomy with or without concomitant oophorectomy: estrogen alone is not enough. 2000 , 9, 917-23	18
114	Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. 2000 , 101, 1594-7	147
113	Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle-aged Swedish men and women: results from the MalmDiet and Cancer Study. 2000 , 152, 334-46	96
112	Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women. 2000 , 36, 217-22	16
111	Mechanisms of estrogen action in the cardiovascular system. 2000 , 74, 337-43	113
110	Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. 2000 , 10, 401-8	103
109	17 Beta-estradiol-stimulated nitric oxide production by neutrophils: effect on platelet activation. 2000 , 95, 284-90	16
108	Ascorbic acid enhances 17 beta-estradiol-mediated inhibition of oxidized low density lipoprotein formation. 2000 , 150, 275-84	28
107	Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. 2000 , 36, 2154-9	97
106	Sex differences and the effects of sex hormones on hemostasis and vascular reactivity. 2001 , 30, 401-26; quiz 427-8	63
105	The effects of hormone replacement therapy on lipid peroxidation and antioxidant status. 2001 , 38, 165-70	31

104	Controversial issues in climacteric medicine (I) Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop, 13-16 October 2000, Royal Society of Medicine, London, UK. 2001 , 38, 263-71	6
103	Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein. 2001 , 1532, 173-84	36
102	How progestins influence the cardiovascular effect of hormone replacement therapy. 2001 , 15 Suppl 6, 9-17	5
101	Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. 2001 , 276, 3459-67	286
100	Case-control study of nonfatal myocardial infarction in relation to selected foods in Japanese men and women. 2001 , 65, 200-6	48
99	Cardioprotective benefits of hormone replacement therapy. 2001 , 13, 69-76; quiz 77-9	
98	Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. 2001 , 21, 243-8	54
97	Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. 2001 , 135, 939-53	498
96	Estrogen causes dynamic alterations in endothelial estrogen receptor expression. 2002 , 91, 814-20	108
95	Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. 2002 , 22, 1692-7	67
94	Estrogen modulation of endothelial nitric oxide synthase. 2002 , 23, 665-86	422
93	Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy. 2002 , 10, 51-60	30
92	A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. 2002 , 77, 945-51	64
91	Exercise-induced muscle damage and the potential protective role of estrogen. 2002 , 32, 103-23	105
90	17-Beta-estradiol protects the liver against warm ischemia/reperfusion injury and is associated with increased serum nitric oxide and decreased tumor necrosis factor-alpha. 2002 , 132, 302-9	72
89	A novel concept to preserve the beneficial effects of hormone replacement therapy in bilaterally female ovariectomized rats: role of lovastatin therapy. 2002 , 45, 167-73	7
88	The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women. 2002 , 3, 53-63	8
87	In vitro pro- and antioxidant properties of estrogens. 2002 , 81, 227-36	47

86	Carotid intima-media thickness in surgical menopause: women who received HRT versus who did not. 2002 , 42, 37-43	9
85	17Beta-estradiol rapid stimulation of rat aorta NOS activity is prevented by oestrogen deficiency. 2002 , 43, 55-64	5
84	Effect of gender on endothelium-dependent dilation to bradykinin in human adipose microvessels. 2002 , 283, H845-52	23
83	Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review. 2002 , 187, 1101-16	35
82	Idoxifene causes endothelium-dependent, nitric oxide-mediated vasorelaxation in male rats. 2002 , 446, 139-43	7
81	Update on cardiovascular disease in post-menopausal women. 2002 , 16, 329-55	60
80	Postmenopausal hormone replacement therapy as antiatherosclerotic therapy. 2002 , 4, 52-8	9
79	Hormone replacement therapy and cardioprotection: the end of the tale?. 2003 , 997, 351-7	30
78	17beta-estradiol inhibits NADPH oxidase activity through the regulation of p47phox mRNA and protein expression in THP-1 cells. 2003 , 1640, 113-8	38
77	The influence of sex hormones on ocular blood flow in women. 2003 , 81, 617-24	45
76	Hormone therapy: the Women's Health Initiative has caused confusion and concern. 2003 , 80, 491-3	5
75	Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. 2003 , 166, 163-70	36
74	Regulation of nitric oxide-dependent vasodilation in coronary arteries of estrogen receptor-alpha-deficient mice. 2003 , 285, H2150-7	25
73	Estrogen-related receptor alpha 1 up-regulates endothelial nitric oxide synthase expression. 2003 , 100, 14451-6	90
72	Effects of tibolone on cell adhesion molecules in postmenopausal women. 2003 , 10, 218-21	6
71	Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. 2004 , 33, 445-453	7
70	Molecular, endocrine, and genetic mechanisms of arterial calcification. 2004 , 25, 629-72	215
69	Tratamiento hormonal sustitutivo en la prevención de cardiopatía isquémica en la menopausia. 2004 , 30, 391-396	1

68	[Controversies on the arterial risk of hormone substitution treatment]. 2004 , 59, 63-70	
67	Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study. 2005 , 12, 40-8	31
66	[Stress and heart disease in women]. 2005 , 30, 416-28; quiz 429-30	9
65	The association of total antioxidant capacity with sex hormones. 2005 , 39, 172-6	43
64	1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. 2005 , 8, 352-9	15
63	Which progestogen is more likely to increase the risk of fatal myocardial infarction: a combination of epidemiological and trial evidence. 2006 , 54, 154-63	6
62	The effect of oestrogen on cytokine and antioxidant levels in male to female transsexual patients. 2006 , 55, 14-8	23
61	Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?. 2006 , 1092, 341-8	35
60	Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women. 2006 , 274, 9-12	2
59	Current state of hormone replacement therapy: the case for using trimegestone. 2006 , 2, 539-50	1
58	Hormones and cardiovascular health in women. 2006 , 12, 483-97	72
57	Soy protein concentrate lowers serum high-density lipoprotein cholesterol concentrations compared with casein in ovariectomized rats fed a low-fat, cholesterol-free diet. 2007 , 27, 417-422	8
56	Therapeutic management of acute intracerebral haemorrhage. 2007 , 8, 3097-116	13
55	Association of socioeconomic status measured by education and risk factors for carotid atherosclerosis: cross-sectional study. 2008 , 49, 824-31	12
54	Cardiovascular aspects of menopausal hormone replacement therapy. 2009 , 12 Suppl 1, 41-6	24
53	Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. 2009 , 10, 85-92	23
52	Every obese male with type 2 diabetes should be screened for hypogonadism 2011 , 28, 14-17b	
51	Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause: A narrative review. 2017 , 104, 44-53	20

50	Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. 2020 , 142, e506-e532	90
49	Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. 2021 , 42, 720-752	6
48	Sex Hormones and the Vasculature. 1996 , 225-237	9
47	Estradiol modulates the sodium pump in the heart sarcolemma. 1997 , 113-118	1
46	Tithonusism. 2000 , 11-21	2
45	A Review of the Epidemiology of Postmenopausal Estrogens and the Risk of Coronary Heart Disease. 1992 , 177-197	2
44	Epidemiologic Studies on Ert and Cardioprotection: State of the Art on HRT and Cardiovascular Disease. 1994 , 133-147	2
43	Atherosclerosis and Estrogen Replacement Therapy. 1994 , 81-88	2
42	Effect of Estrogen on Anatomical and Functional Sequelae of Coronary Artery Disease. 1997 , 111-117	1
41	Cardiovascular Pathophysiology. 2000 , 229-243	1
40	The Epidemiology of Cardiovascular Disease and Postmenopausal Hormone Therapy. 2000 , 543-552	1
39	Menopause and Hormone Replacement Therapy. 1993 , 9, 33-55	27
38	Estrogens, Lipids, and Heart Disease. 1993 , 9, 57-67	15
37	Hormone replacement therapy: primary and secondary prevention. 2001 , 15, 1-25; quiz 109-10	1
36	Physiological concentrations of 17beta-estradiol inhibit the synthesis of nitric oxide synthase in macrophages via a receptor-mediated system. 1998 , 31, 292-8	74
35	Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. 1997 , 17, 217-21	272
34	17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. 1995 , 92, 24-30	358
33	Estrogen replacement. 1996 , 94, 2699-702	21

32	No association of menopause and hormone replacement therapy with carotid artery intima-media thickness. Atherosclerosis Risk in Communities (ARIC) Study Investigators. 1996 , 94, 1857-63	44
31	Antioxidant protection of LDL by physiological concentrations of 17 beta-estradiol. Requirement for estradiol modification. 1997 , 95, 1378-85	104
30	Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. 1997 , 95, 1505-14	193
29	Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca(2+)-dependent K+ channels. 1996 , 79, 1024-30	181
28	Estrogen inhibits the response-to-injury in a mouse carotid artery model. 1995 , 96, 2482-8	195
27	Hormone Therapy and the Primary and Secondary Prevention of Cardiovascular Disease. 2000 , 1-10	
26	Hormontherapie der KHK bei Frauen: Kardioprotektion oder Risiko?. 2002 , 123-136	
25	Menopause and Hormone Replacement Therapy. 2002 , 417-474	
24	Hormone Replacement Therapy and Cardioprotection. 2004 , 255-262	
23	17_β-Estradiol-eluting stents. 2005 , 471-481	
22	HORMONAL MANAGEMENT OF THE SICK MENOPAUSAL WOMAN. 1994 , 21, 231-244	6
21	Oestrogens and Thrombosis. 1990 , 223-248	1
20	Management of Female Menopause. 1990 , 115-135	
19	Hormone Replacement Therapy and Coronary Heart Disease. 1990 , 17, 741-757	8
18	El climaterio. ¿Cambio fisiológico o enfermedad?. 1991 , 42, 187-196	
17	Ovarian Hormones and Arterial Function. 1994 , 185-195	
16	Cardiovascular Disease in Women: Influence of Hormonal Replacement Therapy. 1994 , 27-44	
15	Klimakterium der Frau. 1994 , 513-588	1

14	Treatment of Hyperlipidemia in Women. 1996 , 425-438	
13	Regression/progression in women: the estrogen angiographic trials. 1996 , 133-143	
12	Cardioprotection by Hormone Replacement Therapy. 1996 , 299-311	
11	Estrogen, Nitric Oxide, and Primate Atherosclerosis. 1997 , 233-245	
10	The Female Climacteric. 1997 , 455-515	
9	HRT and the Secondary Prevention of Coronary Heart Disease. 1997 , 125-128	
8	Estrogen and the Heart. 1999 , 219-233	
7	Cardiovascular System. 1999 , 129-140	
6	Frauen und Herzerkrankung. 1999 , 137-146	
5	Action of Specific Estrogens on Vascular Cells. 1999 , 53-58	
4	Management of hypercholesterolaemia in postmenopausal women. 1989 , 151, 299-300	
3	Estradiol modulates the sodium pump in the heart sarcolemma. 1997 , 176, 113-8	10
2	BENEFITS AND RISKS OF HORMONE/ESTROGEN REPLACEMENT. 1996 , 31, 815-825	1
1	WOMEN'S CARDIOVASCULAR HEALTH. 1997 , 24, 1-14	0